tavapadon tavapadon tavapadon (developmental code names cvl-751, pf-6649751, pf-06649751) is a dopamine receptor agonist which is under development by pfizer and cerevel therapeutics for the treatment of parkinson's disease. it acts as a selective partial agonist of the dopamine d1 (ki = 8.54 nm) and d5 receptors. it also shows biased agonism for gs-coupled signaling. as of july 2021, tavapadon is in phase 3 clinical trials for parkinson's disease. tavapadonclinical dataother namescvl-751; pf-6649751; pf-06649751identifiers iupac name 1,5-dimethyl-6-oxyphenyl]pyrimidine-2,4-dione cas number1643489-24-0pubchem cid86764100chemspider48062699uniipt4p8mjp8lkeggd11431chemblchembl3697617chemical and physical dataformulac19h16f3n3o3molar mass391.350 g·mol−13d model (jsmol)interactive image smiles cc1=c(c=cc(=c1)oc2=c(c=cc=n2)c(f)(f)f)c3=c(c(=o)nc(=o)n3c)c inchi inchi=1s/c19h16f3n3o3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9h,1-3h3,(h,24,26,27)key:akqxqlunfkdzbn-uhfffaoysa-n